Hikma Pharmaceuticals Plc, Shire PLC And AstraZeneca plc All Look Attractive After Recent Declines

Have share price falls made Hikma Pharmaceuticals Plc (LON: HIK), Shire PLC (LON: SHP) and AstraZeneca plc (LON: AZN) strong buys?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market’s recent declines have thrown up some great bargains for Foolish investors who aren’t afraid to invest against the grain. Three such bargains are Hikma Pharmaceuticals (LSE: HIK), Shire (LSE: SHP) and AstraZeneca (LSE: AZN).

These three highly defensive pharma stocks are now trading at their lowest valuations in more than two years, presenting a rare opportunity for long-term investors. 

Pipeline worries 

2016 is going to be a tough year for Astra. The company is set to lose patent protection on its blockbuster Crestor blood thinner this year, and at the beginning of February management warned that as a result of patent expirations, Astra’s sales and earnings would fall by a “low to mid-single-digit percentage” in 2016. Many City analysts believe that Astra’s sales declines will be at the lower end of the range mentioned above. 

Still, while Astra’s earnings are set to fall next year, management believes the company is still on track to increase revenues by three-quarters to $45bn by 2023. Astra’s management is pinning its hopes on the group’s best-in-class pipeline of opportunities, new drugs such as Brilinta, an anti-clotting drug, Durvalumab, and AZD9291. What’s more, to complement organic product development, Astra acquired several assets in a $10bn shopping spree last year to bolster its product pipeline and the group has had some success recently with the development of new oncology drugs. 

All in all, Astra’s near-term outlook might be worrying, but as new treatments come to market, the group should return to growth. Investors will get paid to wait for the company’s recovery as Astra currently supports a yield of 4.8%. The payout is covered one-and-a-half times by earnings per share, so it looks safe for now. 

Deal concerns 

Market jitters have pushed Shire’s shares to a 52-week low this week despite the fact that the company is now in a stronger position that it ever has been before. A string of deals has strengthened the company’s treatment pipeline, and pre-tax profit is expected to grow by 11% this year. Earnings per share are set to increase by 12% for 2016 and after recent declines, the company’s shares are trading at a forward P/E of only 16, a five-year low excluding one-off items. 

Shire’s shares currently support a dividend yield of 0.4%, which isn’t much, but the payout is covered more than 15 times by earnings per share, leaving plenty of room for payout growth. 

Buyout jitters 

Last year, Hikma agreed to pay $2.65bn in cash and shares for peer Roxane. However yesterday, Hikma said Roxane’s sales in 2015 were lower than the $680m it had estimated. As a result, Roxane’s price tag has been reduced, from $1.18bn to $647m. Hikma is buying Roxane for its pipeline, not the company’s products. In theory if everything goes to plan, over the long-term Hikma should benefit from the sudden reduction in price. 

Hikma’s earnings per share have expanded 130% since 2010 and City analysts have pencilled-in EPS growth of 16% for 2016. Based on this forecast the company is trading at a forward P/E of 23.2. Hikma’s shares only offer a token dividend yield of 0.7%, although the payout is covered five times by earnings per share. If the company can repeat its performance of the last five years, a valuation of 23.2 times earnings for Hikma’s shares seems appropriate. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

The Barclays share price has soared 72% in 2024. Is it too late for me to buy?

I'm looking for a bank stock to buy in early 2025. The 2024 Barclays share price rise has made the…

Read more »

Investing Articles

2 lessons from the HSBC share price soaring 159% in four years

Christopher Ruane looks at the incredible performance of the HSBC share price in recent years and learns some lessons for…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

After a 2,342% rise, could this FTSE 250 stock keep going?

This FTSE 250 stock boasts a highly cash-generative business model and has been flying for years. Is it time to…

Read more »

Investing Articles

It’s up 70%, but the experts expect the IAG share price to climb still further

Why didn't I buy when I was convinced the IAG share price was likely to soar? And is there still…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

2 UK stocks with recovering profit margins

This writer considers a pair of UK stocks with very different share price trajectories following the pandemic. Would he buy…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

Will Trump’s tariffs squeeze this FTSE 100 giant’s profits?

Our writer looks at how the latest news around US tariffs might impact FTSE 100 company Diageo. Should he be…

Read more »

Investing Articles

Up 95%, is this FTSE winner the best high-yield star for me to buy now?

Do we have to choose between share price growth and high-yield dividends? In this case, over the past year, it…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

2 dividend-paying FTSE shares that could benefit from the AI revolution

Our writer examines two dividend-paying FTSE shares and explains some of the opportunities and risks he sees in their exposure…

Read more »